These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11008360)

  • 1. [Tumorogenesis and mdm2 protein].
    Flores C; Sobrevia L
    Rev Med Chil; 2000 May; 128(5):539-46. PubMed ID: 11008360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mdm2: keeping p53 under control.
    Piette J; Neel H; Maréchal V
    Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
    Skomedal H; Kristensen GB; Lie AK; Holm R
    Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mdm2 proto-oncogene.
    Haines DS
    Leuk Lymphoma; 1997 Jul; 26(3-4):227-38. PubMed ID: 9322885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
    Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
    Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
    Dubs-Poterszman MC; Tocque B; Wasylyk B
    Oncogene; 1995 Dec; 11(11):2445-9. PubMed ID: 8570197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
    Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
    Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of a gene encoding a p53-associated protein in human sarcomas.
    Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B
    Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mdm2, p53 and the cell cycle: when well enough is best left alone].
    Maréchal V
    Pathol Biol (Paris); 1997 Dec; 45(10):824-32. PubMed ID: 9769946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
    Watanabe T; Ichikawa A; Saito H; Hotta T
    Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between the retinoblastoma protein and the oncoprotein MDM2.
    Xiao ZX; Chen J; Levine AJ; Modjtahedi N; Xing J; Sellers WR; Livingston DM
    Nature; 1995 Jun; 375(6533):694-8. PubMed ID: 7791904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.
    Landers JE; Haines DS; Strauss JF; George DL
    Oncogene; 1994 Sep; 9(9):2745-50. PubMed ID: 8058341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
    Lin J; Jin X; Page C; Sondak VK; Jiang G; Reynolds RK
    Cancer Res; 2000 Oct; 60(20):5895-901. PubMed ID: 11059788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus.
    Guenova M; Rassidakis GZ; Gorgoulis VG; Angelopoulou MK; Siakantaris MR; Kanavaros P; Pangalis GA; Kittas C
    Mod Pathol; 1999 Nov; 12(11):1062-71. PubMed ID: 10574604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
    Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
    Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Montes de Oca Luna R; Wagner DS; Lozano G
    Nature; 1995 Nov; 378(6553):203-6. PubMed ID: 7477326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
    Foulkes WD; Stamp GW; Afzal S; Lalani N; McFarlane CP; Trowsdale J; Campbell IG
    Br J Cancer; 1995 Oct; 72(4):883-8. PubMed ID: 7547235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].
    Ayrault O; Zindy F; Roussel MF
    Med Sci (Paris); 2007 Apr; 23(4):356-8. PubMed ID: 17433223
    [No Abstract]   [Full Text] [Related]  

  • 19. The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells.
    Dilla T; Velasco JA; Medina DL; González-Palacios JF; Santisteban P
    Endocrinology; 2000 Jan; 141(1):420-9. PubMed ID: 10614665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mdm2: a bridge over the two tumour suppressors, p53 and Rb.
    Yap DB; Hsieh JK; Chan FS; Lu X
    Oncogene; 1999 Dec; 18(53):7681-9. PubMed ID: 10618708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.